Acasti Pharma, Inc. (ACST)
NASDAQ:ACST
Holding ACST?
Track your performance easily

Acasti Pharma (ACST) Income Statement

1,140 Followers

Acasti Pharma Income Statement

Last quarter (Q1 2025), Acasti Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Acasti Pharma's net income was $-2.62M. See Acasti Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 24Mar 23Mar 22Mar 21Mar 20
Total Revenue
----$ 196.00K$ 0.00
Cost of Revenue
----$ 76.00K$ 0.00
Gross Profit
----$ 120.00K$ 0.00
Operating Expense
$ 13.36M$ 12.85M$ 18.25M$ 15.34M$ 10.84M$ 24.44M
Operating Income
$ -14.85M$ -12.85M$ -18.25M$ -15.34M$ -10.72M$ -24.44M
Net Non Operating Interest Income Expense
$ 1.01M$ 911.00K$ 246.00K$ 224.00K$ -107.00K$ 43.00K
Other Income Expense
$ 1.33M$ 2.73M$ 33.90M$ -4.95M$ 2.69M$ -1.12M
Pretax Income
$ -13.71M$ -14.69M$ -51.97M$ -9.87M$ -19.89M$ -25.51M
Tax Provision
$ -2.27M$ -1.83M$ -9.54M$ -648.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -11.45M$ -12.85M$ -42.43M$ -9.22M$ -19.89M$ -25.51M
Basic EPS
$ -1.15$ -1.35$ -0.95$ -0.27$ -10.64K$ -2.40
Diluted EPS
$ -1.15$ -1.35$ -0.95$ -0.27$ -10.64K$ -2.40
Basic Average Shares
$ 41.61M$ 9.53M$ 44.61M$ 36.84M$ 1.85B$ 10.57M
Diluted Average Shares
$ 41.61M$ 9.53M$ 44.61M$ 36.84M$ 1.85B$ 10.57M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 13.36M$ 12.85M$ 18.25M$ 15.34M$ -10.91M$ 24.44M
Net Income From Continuing And Discontinued Operation
$ -11.45M$ -12.85M$ -42.43M$ -9.22M$ -19.89M$ -25.51M
Normalized Income
$ -15.98M$ -16.52M$ -27.61M$ -10.27M$ -8.65M$ -24.39M
Interest Expense
-----$ 247.00K
EBIT
$ -13.71M$ -14.69M$ -51.97M$ -9.87M$ -19.89M$ -25.27M
EBITDA
$ -13.71M$ -14.67M$ -51.85M$ -9.87M$ -18.97M$ -22.95M
Currency in USD

Acasti Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis